{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:09:03Z","timestamp":1793938143350,"version":"4.8.0"},"reference-count":67,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"unspecified","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["bmjonc"],"accepted":{"date-parts":[[2024,9,12]]},"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:p>Clinical endpoints, such as overall survival, directly measure relevant outcomes. Surrogate endpoints, in contrast, are intermediate, stand-in measures of various tumour-related metrics and include tumour growth, tumour shrinkage, blood results, etc. Surrogates may be a time point measurement, that is, tumour shrinkage at some point (eg, response rate) or biomarker-assessed disease status, measured at given time points (eg, circulating tumour DNA, ctDNA). They can also be measured over time, as with progression-free survival, which is the time until a patient presents with either disease progression or death. Surrogates are increasingly used in trials supporting the marketing authorisation of novel oncology drugs. Yet, the trial-level correlation between surrogates and clinical endpoints\u2014meaning to which extent an improvement in the surrogate predicts an improvement in the direct endpoint\u2014is often moderate to low. Here, we provide a comprehensive classification of surrogate endpoints: time point measurements and time-to-event endpoints in solid and haematological malignancies. Also, we discuss an overlooked aspect of the use of surrogates: the limitations of surrogates outside trial settings, at the bedside. Surrogates can result in the inappropriate stopping or switching of therapy. Surrogates can be used to usher in new strategies (eg, ctDNA in adjuvant treatment of colon cancer), which may erode patient outcomes. In liquid malignancies, surrogates can mislead us to use novel drugs and replace proven standards of care with costly medications. Surrogates can lead one to intensify treatment without clear improvement and possibly worsening quality of life. Clinicians should be aware of the role of surrogates in the development and regulation of drugs and how their use can carry real-world, bedside implications.<\/jats:p>","DOI":"10.1136\/bmjonc-2024-000364","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T15:50:27Z","timestamp":1727970627000},"page":"e000364","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Bedside implications of the use of surrogate endpoints in solid and haematological cancers: implications for our reliance on PFS, DFS, ORR, MRD and more"],"prefix":"10.1136","volume":"3","clinical-trial-number":[{"clinical-trial-number":"nct01526928","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Timoth\u00e9e","family":"Olivier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7876-3978","authenticated-orcid":false,"given":"Alyson","family":"Haslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagney","family":"Ochoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5489-5095","authenticated-orcid":false,"given":"Eduardo","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,10,2]]},"reference":[{"key":"2024100205250518000_3.1.e000364.1","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S1470-2045(24)00015-9","article-title":"Considerations for using potential surrogate endpoints in cancer screening trials","volume":"25","author":"Webb","year":"2024","journal-title":"Lancet Oncol"},{"key":"2024100205250518000_3.1.e000364.2","doi-asserted-by":"crossref","unstructured":"Kemp R , Prasad V . Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? BMC Med 2017;15. doi:10.1186\/s12916-017-0902-9","DOI":"10.1186\/s12916-017-0902-9"},{"key":"2024100205250518000_3.1.e000364.3","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2023-003585","article-title":"Can earlier biomarker measurements explain a treatment effect on diabetes incidence? A robust comparison of five surrogate markers","volume":"11","author":"Parast","year":"2023","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2024100205250518000_3.1.e000364.4","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","article-title":"The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses","volume":"175","author":"Prasad","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2024100205250518000_3.1.e000364.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.11.012"},{"key":"2024100205250518000_3.1.e000364.6","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31957"},{"key":"2024100205250518000_3.1.e000364.7","unstructured":"Cooper GM . The Development and Causes of Cancer. 2nd edn. Sinauer Associates, 2000."},{"key":"2024100205250518000_3.1.e000364.8","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41571-023-00823-5","article-title":"Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed","volume":"20","author":"Walia","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2024100205250518000_3.1.e000364.9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jcpo.2018.04.001","article-title":"The US Food and Drug Administration\u2019s use of pathologic complete response as regulatory endpoint: Did it pay off?","volume":"16","author":"Luo","year":"2018","journal-title":"J Cancer Policy"},{"key":"2024100205250518000_3.1.e000364.10","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-066381","article-title":"Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis","volume":"375","author":"Conforti","year":"2021","journal-title":"BMJ"},{"key":"2024100205250518000_3.1.e000364.11","doi-asserted-by":"crossref","unstructured":"Ivanovic N , Bjelica D , Loboda B , et al . Changing the role of pCR in breast cancer treatment - an unjustifiable interpretation of a good prognostic factor as a \u2018factor for a good prognosis. Front Oncol 2023;13. doi:10.3389\/fonc.2023.1207948","DOI":"10.3389\/fonc.2023.1207948"},{"key":"2024100205250518000_3.1.e000364.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70336-9"},{"key":"2024100205250518000_3.1.e000364.13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1268"},{"key":"2024100205250518000_3.1.e000364.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703643"},{"key":"2024100205250518000_3.1.e000364.15","doi-asserted-by":"crossref","unstructured":"Loibl S , Jassem J , Sonnenblick A , et al . Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update. J Clin Oncol 2024.:JCO2302505. doi:10.1200\/JCO.23.02505","DOI":"10.1200\/JCO.23.02505"},{"key":"2024100205250518000_3.1.e000364.16","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/j.clon.2019.05.003","article-title":"Generalisability of Common Oncology Clinical Trial Eligibility Criteria in the Real World","volume":"31","author":"Karim","year":"2019","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2024100205250518000_3.1.e000364.17","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0478"},{"key":"2024100205250518000_3.1.e000364.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857"},{"key":"2024100205250518000_3.1.e000364.19","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1001\/jamaoncol.2016.5296","article-title":"Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World","volume":"3","author":"Mailankody","year":"2017","journal-title":"JAMA Oncol"},{"key":"2024100205250518000_3.1.e000364.20","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1016\/S2666-7568(21)00092-1","article-title":"Observed and expected serious adverse event rates in randomised clinical trials for hypertension: an observational study comparing trials that do and do not focus on older people","volume":"2","author":"Hanlon","year":"2021","journal-title":"Lancet Healthy Longev"},{"key":"2024100205250518000_3.1.e000364.21","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9453"},{"key":"2024100205250518000_3.1.e000364.22","doi-asserted-by":"crossref","unstructured":"Tie J , Wang Y , Tomasetti C , et al . Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 2016;8. doi:10.1126\/scitranslmed.aaf6219","DOI":"10.1126\/scitranslmed.aaf6219"},{"key":"2024100205250518000_3.1.e000364.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200075"},{"key":"2024100205250518000_3.1.e000364.24","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-023-03037-9","article-title":"Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer","volume":"21","author":"Olivier","year":"2023","journal-title":"BMC Med"},{"key":"2024100205250518000_3.1.e000364.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.022"},{"key":"2024100205250518000_3.1.e000364.26","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1200\/JCO.21.02538","article-title":"Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update","volume":"40","author":"Baxter","year":"2022","journal-title":"J Clin Oncol"},{"key":"2024100205250518000_3.1.e000364.27","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-022-02589-6","article-title":"Molecular testing to deliver personalized chemotherapy recommendations: risking over and undertreatment","volume":"20","author":"Olivier","year":"2022","journal-title":"BMC Med"},{"key":"2024100205250518000_3.1.e000364.28","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2022.1026"},{"key":"2024100205250518000_3.1.e000364.29","doi-asserted-by":"crossref","unstructured":"Gibbs P , Hong W , Tie J . Re: Molecular testing to deliver personalised chemotherapy recommendations. BMC Med 2023;21. doi:10.1186\/s12916-023-03036-w","DOI":"10.1186\/s12916-023-03036-w"},{"key":"2024100205250518000_3.1.e000364.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"2024100205250518000_3.1.e000364.31","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/onco.13637","article-title":"ADAURA: Mature Enough for Publication, Not for Prime Time","volume":"26","author":"Addeo","year":"2021","journal-title":"Oncologist"},{"key":"2024100205250518000_3.1.e000364.32","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N Engl J Med"},{"key":"2024100205250518000_3.1.e000364.33","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/cncr.35112","article-title":"Lessons from ADAURA: Can we improve on a positive trial?","volume":"130","author":"West","year":"2024","journal-title":"Cancer"},{"key":"2024100205250518000_3.1.e000364.34","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-023-10917-z","article-title":"Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020","volume":"23","author":"Olivier","year":"2023","journal-title":"BMC Cancer"},{"key":"2024100205250518000_3.1.e000364.35","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1001\/jamaoncol.2024.1569","article-title":"Postrecurrence Treatment in Neoadjuvant or Adjuvant FDA Registration Trials: A Systematic Review","volume":"10","author":"Olivier","year":"2024","journal-title":"JAMA Oncol"},{"key":"2024100205250518000_3.1.e000364.36","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ygyno.2014.10.029","article-title":"Risk of second cancers cancer after a first primary breast cancer: a systematic review and meta-analysis","volume":"136","author":"Molina-Montes","year":"2015","journal-title":"Gynecol Oncol"},{"key":"2024100205250518000_3.1.e000364.37","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv106"},{"key":"2024100205250518000_3.1.e000364.38","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/ajh.26867","article-title":"Is it time to reconsider molecular response milestones in chronic myeloid leukemia?","volume":"98","author":"Walia","year":"2023","journal-title":"Am J Hematol"},{"key":"2024100205250518000_3.1.e000364.39","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1200\/JCO.20.03613","article-title":"Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0","volume":"39","author":"Tolaney","year":"2021","journal-title":"J Clin Oncol"},{"key":"2024100205250518000_3.1.e000364.40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114192","article-title":"CDK4\/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms","volume":"207","author":"Haslam","year":"2024","journal-title":"Eur J Cancer"},{"key":"2024100205250518000_3.1.e000364.41","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30717-9"},{"key":"2024100205250518000_3.1.e000364.42","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamainternmed.2019.0583","article-title":"An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate","volume":"179","author":"Chen","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2024100205250518000_3.1.e000364.43","unstructured":"Corixa Corporation. BEXXAR (tositumomab and iodine I 131 tositumomab. 2003."},{"key":"2024100205250518000_3.1.e000364.44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.4101"},{"key":"2024100205250518000_3.1.e000364.45","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1001\/jamainternmed.2014.5756","article-title":"The withdrawal of drugs for commercial reasons: the incomplete story of tositumomab","volume":"174","author":"Prasad","year":"2014","journal-title":"JAMA Intern Med"},{"key":"2024100205250518000_3.1.e000364.46","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.3981","article-title":"Assessment of Accuracy of Waterfall Plot Representations of Response Rates in Cancer Treatment Published in Medical Journals","volume":"PMCID","author":"Kim","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2024100205250518000_3.1.e000364.47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.2514"},{"key":"2024100205250518000_3.1.e000364.48","doi-asserted-by":"crossref","first-page":"100301","DOI":"10.1016\/j.jcpo.2021.100301","article-title":"Patient perspectives of value of delayed disease progression on imaging (imaging PFS). A treatment trade-off experiment","volume":"30","author":"Robinson","year":"2021","journal-title":"J Cancer Policy"},{"key":"2024100205250518000_3.1.e000364.49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073"},{"key":"2024100205250518000_3.1.e000364.50","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu456"},{"key":"2024100205250518000_3.1.e000364.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.07.005"},{"key":"2024100205250518000_3.1.e000364.52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096316","article-title":"Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example","volume":"9","author":"Burotto","year":"2014","journal-title":"PLoS One"},{"key":"2024100205250518000_3.1.e000364.53","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"The Lancet"},{"key":"2024100205250518000_3.1.e000364.54","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(23)00616-2","article-title":"The fate of sotorasib: a regulatory failure potentially harming patients","volume":"25","author":"Ranganathan","year":"2024","journal-title":"Lancet Oncol"},{"key":"2024100205250518000_3.1.e000364.55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903387"},{"key":"2024100205250518000_3.1.e000364.56","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1002\/cncr.32979","article-title":"Olaparib for BRCA mutant pancreas cancer: Should the POLO trial change clinical practice?","volume":"126","author":"Nishikawa","year":"2020","journal-title":"Cancer"},{"key":"2024100205250518000_3.1.e000364.57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"2024100205250518000_3.1.e000364.58","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood.2021014586","article-title":"Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy","volume":"140","author":"Wang","year":"2022","journal-title":"Blood"},{"key":"2024100205250518000_3.1.e000364.59","unstructured":"MedGen - NCBI . Residual disease (concept id: c0543478). NCBI. Available: https:\/\/www.ncbi.nlm.nih.gov\/medgen\/108162#:~:text=Definition [Accessed 26 Jun 2024]."},{"key":"2024100205250518000_3.1.e000364.60","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"key":"2024100205250518000_3.1.e000364.61","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/jamaoncol.2016.5660","article-title":"Myeloma Minimal Residual Disease and Surrogacy","volume":"3","author":"Little","year":"2017","journal-title":"JAMA Oncol"},{"key":"2024100205250518000_3.1.e000364.62","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/jamaoncol.2017.0404","article-title":"Myeloma Minimal Residual Disease and Surrogacy\u2014Reply","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"key":"2024100205250518000_3.1.e000364.63","doi-asserted-by":"crossref","unstructured":"Mateos M-V , Paiva B , Teresa Cedena Romer M , et al . GEM2017FIT trial: induction therapy with bortezomib-melphalan and prednisone (vmp) followed by lenalidomide and dexamethasone (rd) versus carfilzomib, lenalidomide and dexamethasone (krd) plus\/minus daratumumab (d), 18 cycles, followed by consolidation and maintenance therapy with lenalidomide and daratumumab: phase iii, multicenter, randomized trial for elderly fit newly diagnosed multiple myeloma (ndmm) patients aged between 65 and 80 years. ASH; 2023. Available: https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper179866.html [Accessed 26 Jun 2024].","DOI":"10.1182\/blood-2023-179866"},{"key":"2024100205250518000_3.1.e000364.64","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-162388"},{"key":"2024100205250518000_3.1.e000364.65","first-page":"885","article-title":"ASC4FIRST Investigators","volume":"391","author":"Hochhaus","year":"2024","journal-title":"Asciminib in Newly Diagnosed Chronic Myeloid Leukemia N Engl J Med"},{"key":"2024100205250518000_3.1.e000364.66","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamaoncol.2021.0379","article-title":"Evolution of the Randomized Clinical Trial in the Era of Precision Oncology","volume":"7","author":"Del Paggio","year":"2021","journal-title":"JAMA Oncol"},{"key":"2024100205250518000_3.1.e000364.67","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1001\/jamainternmed.2020.1097","article-title":"FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019","volume":"PMCID","author":"Chen","year":"2020","journal-title":"JAMA Intern Med"}],"container-title":["BMJ Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjonc-2024-000364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T15:50:40Z","timestamp":1727970640000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjoncology.bmj.com\/lookup\/doi\/10.1136\/bmjonc-2024-000364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,10,2]]},"published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1136\/bmjonc-2024-000364"],"URL":"https:\/\/doi.org\/10.1136\/bmjonc-2024-000364","relation":{},"ISSN":["2752-7948"],"issn-type":[{"value":"2752-7948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]}}}